Heart failure is a pressing public health problem with no curative treatment currently available. The existing therapies provide symptomatic relief, but are unable to reverse molecular changes that occur in cardiomyocytes. The mechanisms of heart failure are complex and multiple, but mitochondrial dysfunction appears to be a critical factor in the development of this disease. Thus, it is important to focus research efforts on targeting mitochondrial dysfunction in the failing heart in order to revive the myocardium and its contractile function. This review highlights the three promising areas for the development of heart failure therapies, including mitochondrial biogenesis, mitochondrial oxidative stress and mitochondrial iron handling. Moreover, the translational potential of compounds targeting these pathways is discussed.
Bayeva et al. (Wed,) studied this question.